Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)

被引：2
|
作者：
Bracarda, Sergio [1 ]
Antonuzzo, Lorenzo [2 ]
Maruzzo, Marco [3 ]
Santini, Daniele [4 ]
Tambaro, Rosa [5 ]
Buti, Sebastiano [6 ]
Carrozza, Francesco [7 ,8 ]
Calabro, Fabio
Di Lorenzo, Giuseppe [9 ]
Fornarini, Giuseppe [10 ]
Iacovelli, Roberto [11 ]
Cullura, Daniela [12 ]
Messina, Carlo [13 ]
Cerbone, Linda [14 ]
Fazzi, Gennaro [15 ]
Venturini, Filippo [15 ]
Colasanto, Raffaele [15 ]
Necchi, Andrea [16 ]
De Giorgi, Ugo [17 ]
机构：
[1] Azienda Osped Santa Maria, Terni, Italy
[2] Azienda Osped Univ Careggi, Florence, Italy
[3] IOV IRCCS, Ist Oncol Veneto, Padua, Italy
[4] Univ Sapienza Polo Pontino, Rome, Italy
[5] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[6] Univ Parma, Parma, Italy
[7] AUSL Romagna, Ravenna, Italy
[8] IFO Ist Regina Elena, Rome, Italy
[9] ASL SALERNO PO A Tortora, Pagani, Italy
[10] IRCCS Osped Policlin San Martino, Genoa, Italy
[11] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[12] Ist Europeo Oncol IEO, Milan, Italy
[13] Osped ARNAS Civ, Palermo, Italy
[14] Azienda Osped San Camillo Forlanini, Rome, Italy
[15] Merck Serono SPA, Merck KGaA, Rome, Italy
[16] IRCCS San Raffaele Hosp & Sci Inst, Milan, Italy
[17] IRCCS, Ist Romagnolo Studio Tumori IRST Dino Amadori, Meldola, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [31] Overall survival and treatment patterns among real-world patients with locally advanced or metastatic urothelial carcinoma treated with first-line therapy
    Simeone, Jason C.
    Nordstrom, Beth L.
    Patel, Ketan
    Klein, Alyssa B.
    Horne, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [32] Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment
    Barthelemy, Philippe
    Thibault, Constance
    Flechon, Aude
    Gross-Goupil, Marine
    Voog, Eric
    Eymard, Jean-Christophe
    Abraham, Christine
    Chasseray, Matthieu
    Lorgis, Veronique
    Hilgers, Werner
    Gobert, Aurelien
    Le Moulec, Sylvestre
    Simon, Camille
    Nicolas, Emanuel
    Escande, Anne
    Pouessel, Damien
    Mouillet, Guillaume
    Josse, Constant
    Solbes, Marie-Noelle
    Lambert, Prisca
    Loriot, Yohann
    EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (02): : 407 - 416
  • [33] Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility
    Morgans, Alicia K.
    Galsky, Matthew D.
    Wright, Phoebe
    Hepp, Zsolt
    Chang, Nancy
    Willmon, Candice L.
    Sesterhenn, Steve
    Liu, Yutong
    Sonpavde, Guru P.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (08) : 357e11 - 357e21
  • [34] BUDGET IMPACT ANALYSIS OF AVELUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE AS FIRST-LINE (1L) MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED (LA) OR METASTATIC UROTHELIAL CARCINOMA (MUC) IN TAIWAN
    Tsai, Y. C.
    Lin, A. Y.
    Huang, J.
    Wu, E.
    Liu, K.
    Palencia, R.
    Chang, J.
    Kearney, M.
    VALUE IN HEALTH, 2022, 25 (01) : S47 - S47
  • [35] Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.
    Li, Haojie
    Sura, Sneha
    Babcock, Aram
    Herms, Lisa
    Guo, Jinhong
    Conkling, Paul
    Franco, Sonia
    Singhal, Puneet K.
    Mamtani, Ronac
    Bupathi, Manojkumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 560 - 560
  • [36] AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA IN THE JAVELIN BLADDER 100 TRIAL: SUBGROUP ANALYSIS BY DURATION OF TREATMENT-FREE INTERVAL FROM END OF CHEMOTHERAPY TO START OF MAINTENANCE
    Sridhar, Srikala S.
    Powles, Thomas
    Loriot, Yohann
    Climent, Miguel A.
    Gupta, Shilpa
    Tsuchiya, Norihiko
    Bamias, Aristotelis
    Ardizzoni, Andrea
    Ullen, Anders
    Huang, Bo
    Costa, Nuno
    Laliberte, Robert J.
    di Pietro, Alessandra
    Sternberg, Cora N.
    Grivas, Petros
    JOURNAL OF UROLOGY, 2021, 206 : E997 - E997
  • [37] Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma not progressed with first-line chemotherapy: Prespecified subgroup analyses from JAVELIN Bladder 100
    Lumba, Sumit
    Grivas, Petros
    Park, Se Hoon
    Voog, Eric
    Caserta, Claudia
    Valderrama, Begona P.
    Gurney, Howard
    Kalofonos, Haralabos
    Radulovic, Sinisa
    Demey, Wim
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Kopyltsov, Evgeny
    Gupta, Shilpa
    Huang, Bo
    Costa, Nuno
    Blake-Haskins, John A.
    di Pietro, Alessandra
    Powles, Thomas
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 126 - 126
  • [38] Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma not progressed with first-line chemotherapy: prespecified subgroup analyses from JAVELIN Bladder 100
    Lumba, Sumit
    Grivas, Petros
    Park, Se Hoon
    Voog, Eric
    Caserta, Claudia
    Valderrama, Begona P.
    Gurney, Howard
    Kalofonos, Haralabos
    Radulovic, Sinisa
    Demey, Wim
    Ullen, Andres
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Kopyltsov, Evgeny
    Gupta, Shilpa
    Huang, Bo
    Costa, Nuno
    Blake-Haskins, John A.
    di Pietro, Alessandra
    Powles, Thomas
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 42 - 43
  • [39] First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center
    Wang, Bin
    Song, Ji-Wen
    Chen, Hui-Qing
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [40] Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): Results from patients with ≥12 months of treatment in JAVELIN Bladder 100
    Aragon-Ching, Jeanny B.
    Grivas, Petros
    Loriot, Yohann
    Bellmunt, Joaquim
    Pook, David W.
    Wang, Jing
    Michelon, Elisabete
    di Pietro, Alessandra
    Powles, Thomas
    Sridhar, Srikala S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 138 - 139
12345